TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04189744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-sulphadoxine-pyrimethamine plus metronidazole
Description: Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-dihydroartemisinin-piperaquine plus metronidazole
Description: Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPTp-sulphadoxine-pyrimethamine
Description: The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
Study: NCT02601170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma Intra-Articular Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Viscosupplementation
Study: NCT01535833

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Device- Robotic sacral colpopexy
Description: To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
Study: NCT02726490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance
Description: glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
Study: NCT00917241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMI combined with IID
Description: MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy
Study: NCT00917241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMI
Description: MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
Study: NCT00923871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone Beam CT
Description: Patients will also have a CBCT scan when they are having their first IMRT treatment.
Study: NCT01859416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Study: NCT03942835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 1 : Competitive attention test in healthy participants
Description: Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 2 : Competitive attention test in patients with ADHD with no treatment
Description: Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 2 : Competitive attention test in patients with ADHD with no treatment
Description: Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment
Description: Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
Study: NCT02202395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 0.25mg
Description: use LTS 0.25mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 0.5mg
Description: use LTS 0.5mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTS 1.0mg
Description: use LTS 1.0mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: use placebo once daily
Study: NCT02032849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual air-impingement operation
Description: A method which we invented to clear subglottic secretion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subglottic secretion drainage
Description: The conventional method with a special tube to drainage subglottic secretion
Study: NCT05589506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable partial denture PEEK
Description: A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
Study: NCT00542035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1, dose 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: dose 1, dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 2
Study: NCT03005678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: active treatment group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: comparator
Study: NCT06051786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine/fluticasone 137/50 mcg nasal spray
Description: AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista™
Description: Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
Study: NCT04448158

Intervention type: DIAGNOSTIC_TEST
Intervention: Genotypic Resistance Test
Description: A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genotypic Resistance Test
Description: A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing.
Study: NCT01005706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus, sirolimus and steroid
Description: Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
Study: NCT02239198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition bar
Description: The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition bar
Description: The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition bar
Description: The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
Study: NCT03898102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: regorafenib plus zinc gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib plus zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplement
Description: Zinc gluconate supplement
Study: NCT01742559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior middle superior alveolar
Description: The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraperiosteal technique
Description: The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
Study: NCT03499119

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 1
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 1
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 2
Description: Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 334 Dose 3
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
Study: NCT02692417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
Study: NCT00493402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
Study: NCT00282971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin (Exubera)
Description: Addition of inhaled insulin to pre-existing oral diabetes therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
Study: NCT02043054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
Study: NCT02081274

Intervention type: PROCEDURE
Intervention: Surgery for congenital heart disease
Study: NCT02439827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fortaleça sua Saúde program
Description: The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
Study: NCT01719666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction and lateral retinaculum release
Description: MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Description: conventional surgery: MPFL reconstruction
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy
Study: NCT01140854

Intervention type: PROCEDURE
Intervention: Lumbar spine surgery
Description: (non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.

Intervention type: OTHER
Intervention: Neurologic/neuropsychometric examinations
Description: To measure postoperative cognitive dysfunction.

Intervention type: OTHER
Intervention: Neurologic/neuropsychometric examinations
Description: To measure postoperative cognitive dysfunction.
Study: NCT01333696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
Study: NCT04293562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies
Study: NCT04075318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine
Study: NCT04293562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Ancillary studies
Study: NCT04075318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312
Description: A synthetic peptide-based vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01415349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-002358
Description: 1 mg, oral, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-002358 + omeprazole
Description: SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
Study: NCT00933400

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Coronary Angiography (CTCA)
Description: CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Strategy
Description: Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
Study: NCT01970891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular stimulation device
Description: Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.